Skip to content
Medical Health Aged Care, Science

Blood fats predict success of dietary weight loss in pre-diabetes management

Centenary Institute 2 mins read

New research from the Centenary Institute has identified specific blood fats that can predict how effectively individuals with pre-diabetes will improve their blood sugar levels through diet and weight loss. These findings could pave the way for more personalised approaches to preventing and managing type 2 diabetes.

 

Pre-diabetes is a condition where blood sugar levels are higher than normal but not yet in the diabetic range. Weight loss through dieting is a common recommendation to help bring blood sugar levels back to normal. However, more than half of people with pre-diabetes do not achieve normal blood sugar levels after losing weight.

 

This new study, based on samples from 104 participants, aimed to identify biomarkers in the blood that could predict who would benefit most from dietary weight loss. The participants, all with pre-diabetes, lost at least 8% of their body weight through a low-energy diet. Using big data technology and machine learning based bioinformatics, researchers then analysed changes in hundreds of different lipids­­—molecules in the blood that include fats and fatty acids—before and after the diet.

 

Published in The American Journal of Clinical Nutrition, the study found that weight loss led to significant changes in several types of lipids. Importantly, certain lipids measured before the weight loss could predict how much participants' blood sugar levels would improve afterward. For example, certain sphingolipids, a type of fat found in cell membranes, were linked to changes in fasting blood sugar levels, while other lipids were associated with improvements in indicators such as hemoglobin A1c, insulin and insulin resistance.

 

"Our findings reveal that certain fats in the blood can tell us a lot about a person's chances of improving their blood sugar levels through weight loss,” said lead study author, Dr Yanfei (Jacob) Qi from the Centenary Institute’s Centre for Cardiovascular Research.

 

“This could be a game-changer in how we approach diabetes prevention, allowing us to personalise treatment plans for those who are less likely to benefit from standard diet recommendations,” he said.

 

The researchers believe that discovering these lipid biomarkers offers hope for more effective diabetes prevention strategies and better outcomes for those at risk, moving beyond the one-size-fits-all advice currently offered.

 

Next, Dr Qi and his team will assess the power of lipid predictors in a more challenging real-world scenario—a three-year lifestyle intervention through both diet and physical activity for weight control in individuals with pre-diabetes.

 

[ENDS]

 

Publication:

Deep serum lipidomics identifies evaluative and predictive biomarkers for individualized glycemic responses following low-energy diet-induced weight loss: a PREVIEW sub-study.

https://www.sciencedirect.com/science/article/abs/pii/S0002916524007093

 


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

 For more information about the Centenary Institute, visit centenary.org.au


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.